Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397499 | 0.99 | LDHA (0.49) | LDHASLC6A4EPHX1CYP2D6MEN1 | |
| SCHEMBL21715226 | 0.96 | LDHA (0.51) | LDHASLC6A4EPHX1CYP2D6MEN1 | |
| SCHEMBL17009239 | 0.91 | LDHA (0.53) | LDHASLC6A4EPHX1CYP2D6KMT2A | |
| SCHEMBL16762028 | 0.87 | LDHA (0.51) | LDHASLC6A4EPHX1CYP2D6CYP1A2 | |
| SCHEMBL933944 | 0.84 | LDHA (0.54) | LDHASLC6A4EPHX1CYP2D6KMT2A | |
| SCHEMBL7360593 | 0.82 | LDHA (0.56) | LDHASLC6A4EPHX1CYP2D6KMT2A | |
| SCHEMBL27512733 | 0.82 | LDHA (0.56) | LDHASLC6A4EPHX1CYP2D6KMT2A | |
| SCHEMBL17397647 | 0.80 | TAAR1 (0.52) | CYP1A2L3MBTL1 | |
| SCHEMBL6409253 | 0.79 | CYP3A4 (0.54) | CYP2D6MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL8775060 | 0.79 | LDHA (0.65) | LDHACYP2D6MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372253-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma LLC (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023215314-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma LLC (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | 7 HILLS PHARMA INC. | 2021-05-20 | — | — | US | disclosed |
| US-20200054600-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF SOLID TUMORS | 7 HILLS INTERESTS LLC (US) | 2020-02-20 | — | — | US | disclosed |
| EP-3164127-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | 7 HILLS INTERESTS, LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016003980-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | 7 HILLS INTERESTS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054600-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF SOLID TUMORS | VCAM1, ITGB1, ITGA1 | LDHA 1046/4885SLC6A4 4541/4885EPHX1 4118/4885 |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | ITGB7, ITGA1, ITGAL | LDHA 2236/4885SLC6A4 4161/4885EPHX1 1467/4885 |
| US-20230372253-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | ITGAM, ITGA2, ADGRF1 | LDHA 3278/4885SLC6A4 3259/4885EPHX1 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.